Abstract
Breast cancer is the most common malignancy in women in the United States in the year 2000. The proto-oncogene Her-2/neu (c-erb-B2) has become an increasingly important prognostic and predictive factor in breast cancer. Overexpression/amplification of the Her-2/neu has been associated with a worse outcome in patients with breast cancer. Herceptin, a "humanized" murine monoclonal antibody directed against the extracellular domain of the Her-2/neu protein, is being used to treat breast cancer that overexpresses Her-2/neu. The status of Her-2/neu in the tumor has become a critical factor in the management strategy of a breast cancer patient. The objective of this article is to provide a comprehensive review of all aspects of Her-2/neu in breast cancer, including biology, prognostic and predictive value, targeted Herceptin therapy, and the laboratory testing of Her-2/neu.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 139-152 |
| Number of pages | 14 |
| Journal | Diagnostic Molecular Pathology |
| Volume | 10 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 12 2001 |
Keywords
- Breast carcinoma
- C-erb-B2
- Her-2/neu
- Herceptin
- Trastuzumab
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Molecular Biology
- Cell Biology